StockData
ALX Oncology Holdings Inc logo

ALX Oncology Holdings Inc (ALXO) stock

ALXONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 3/30
$0.97−0.03 (-3.47%)

Close on Nov 18, 2026Market cap $134.14MP/E –Yield –

ALX Oncology cash

Cash and short-term investments held at the end of each period.

ALX Oncology's cash was $138.23M at Jun 30, 2026. For fiscal 2025 it was $44.79M, down 65.0% from the year before. The highest annual figure on record is $434.22M in fiscal 2020.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$44.79M-65.0%
FY2024Dec 31, 2024$127.82M-30.1%
FY2023Dec 31, 2023$182.74M-31.4%
FY2022Dec 31, 2022$266.27M-26.8%
FY2021Dec 31, 2021$363.67M-16.2%
FY2020Dec 31, 2020$434.22M+4715.6%
FY2019Dec 31, 2019$9.02M+9.1%
FY2018Dec 31, 2018$8.26M-62.6%
FY2017Dec 31, 2017$22.10M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$138.23M+74.3%
Q1 FY2026Mar 31, 2026$140.32M+43.4%
Q4 FY2025Dec 31, 2025$44.79M-65.0%
Q3 FY2025Sep 30, 2025$60.63M-59.2%
Q2 FY2025Jun 30, 2025$79.31M-49.4%
Q1 FY2025Mar 31, 2025$97.83M-37.9%
Q4 FY2024Dec 31, 2024$127.82M-30.1%
Q3 FY2024Sep 30, 2024$148.57M-21.8%
Q2 FY2024Jun 30, 2024$156.72M-26.4%
Q1 FY2024Mar 31, 2024$157.44M-30.9%
Q4 FY2023Dec 31, 2023$182.74M-31.4%
Q3 FY2023Sep 30, 2023$190.01M-33.3%
Q2 FY2023Jun 30, 2023$212.84M-32.1%
Q1 FY2023Mar 31, 2023$227.94M-28.0%
Q4 FY2022Dec 31, 2022$266.27M-26.8%
Q3 FY2022Sep 30, 2022$284.91M-26.0%
Q2 FY2022Jun 30, 2022$313.37M-23.6%
Q1 FY2022Mar 31, 2022$316.60M-26.3%
Q4 FY2021Dec 31, 2021$363.67M-16.2%
Q3 FY2021Sep 30, 2021$385.15M+48.4%
Q2 FY2021Jun 30, 2021$409.96M+317.9%
Q1 FY2021Mar 31, 2021$429.86M+309.2%
Q4 FY2020Dec 31, 2020$434.22M+4715.6%
Q3 FY2020Sep 30, 2020$259.48M+4296.5%
Q2 FY2020Jun 30, 2020$98.10M+979.5%
Q1 FY2020Mar 31, 2020$105.04M+1171.3%
Q4 FY2019Dec 31, 2019$9.02M-59.2%
Q3 FY2019Sep 30, 2019$5.90M–
Q2 FY2019Jun 30, 2019$9.09M–
Q4 FY2018Dec 31, 2018$8.26M–
Q4 FY2017Dec 31, 2017$22.10M–

More ALX Oncology figures

See a number that looks wrong?